Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 21, 2024 - Issue 2
Submit an article Journal homepage
67
Views
0
CrossRef citations to date
0
Altmetric
Review

Conjugates of amphotericin B to resolve challenges associated with its delivery

Vineet Kumar Jaina Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, IndiaView further author information
,
Keerti Jainb Drug Delivery and Nanomedicine Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) – Raebareli, Lucknow, IndiaCorrespondence[email protected] [email protected]
View further author information
&
Harvinder Poplia Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, IndiaCorrespondence[email protected]
View further author information
Pages 187-210 | Received 23 Aug 2023, Accepted 17 Jan 2024, Published online: 31 Jan 2024

  • Wang X, Mohammad IS, Fan L, et al. Delivery strategies of amphotericin B for invasive fungal infections. Acta Pharm Sin B. 2021;11(8):2585–2604. doi: 10.1016/j.apsb.2021.04.010
  • Chaudhari MB, Desai PP, Patel PA, et al. Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module. Drug Deliv Transl Res. 2015;6(4):354–364. doi: 10.1007/s13346-015-0267-6
  • Faustino C, Pinheiro L. Lipid systems for the delivery of Amphotericin B in antifungal therapy. Pharmaceutics. 2020;12(1):29. doi: 10.3390/pharmaceutics12010029
  • Voncik KS, Fermino BL, Cardoso NCS, et al. Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review. African J Pharm Pharmacol. 2016;10(24):512–520. doi: 10.5897/AJPP2015.4280
  • Souza AC, Amaral AC. Antifungal therapy for systemic mycosis and the nanobiotechnology era: improving efficacy, biodistribution and toxicity. Front Microbiol. 2017;8:336. doi: 10.3389/fmicb.2017.00336
  • Das S, Devarajan PV. Enhancing safety and efficacy by altering the toxic aggregated state of Amphotericin B in lipidic nanoformulations. Mol Pharm. 2020;17(6):2186–2195. doi: 10.1021/acs.molpharmaceut.0c00313
  • Umegawa Y, Yamamoto T, Dixit M, et al. Amphotericin B assembles into seven-molecule ion channels: an NMR and molecular dynamics study. Sci Adv. 2022;8(24):eabo2658. doi: 10.1126/sciadv.abo2658
  • Abdelnasir S, Anwar A, Kawish M, et al. Metronidazole conjugated magnetic nanoparticles loaded with amphotericin B exhibited potent effects against pathogenic Acanthamoeba castellanii belonging to the T4 genotype. AMB Express. 2020;10(1):127. doi: 10.1186/s13568-020-01061-z
  • Grisin T, Bories C, Bombardi M, et al. Supramolecular chitosan micro-platelets synergistically enhance anti-candida albicans activity of Amphotericin B using an immunocompetent murine model. Pharm Res. 2017;34(5):1067–1082. doi: 10.1007/s11095-017-2117-3
  • Iqbal K, Abdalla SAO, Anwar A, et al. Isoniazid Conjugated Magnetic Nanoparticles Loaded with Amphotericin B as a Potent Antiamoebic Agent against Acanthamoeba castellanii. Antibiotics. 2020;9(5):276. doi: 10.3390/antibiotics9050276
  • Thanki K, Prajapati R, Sangamwar AT, et al. Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of Amphotericin B. Int J Pharm. 2018;544(1):1–13. doi: 10.1016/j.ijpharm.2018.04.009
  • Cuddihy G, Wasan EK, Di Y, et al. The development of oral Amphotericin B to treat systemic fungal and parasitic infections: has the myth been finally realized? Pharmaceutics. 2019;11(3):99. doi: 10.3390/pharmaceutics11030099
  • Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 Jun;73(9):919–934. doi: 10.1007/s40265-013-0069-4. PMID: 23729001.
  • Cowen LE, Sanglard D, Howard SJ, et al. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2015;5(7):a019752. doi: 10.1101/cshperspect.a019752
  • Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, et al. Sixty years of Amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10(1):115–147. doi: 10.1007/s40121-020-00382-7
  • Fisher MC, Alastruey-Izquierdo A, Berman J, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20(9):557–571. doi: 10.1038/s41579-022-00720-1
  • Mehta D, Saini V, Bajaj A. Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance. RSC Med Chem. 2023;14(9):1603–1628. doi: 10.1039/D3MD00151B
  • Moraes DC. Recent developments on the anti-Candida effect of amphotericin B combined with a second drug – a mini-review. An Acad Bras Cienc. 2023;95(1):e20220033. doi: 10.1590/0001-3765202320220033
  • Alenazi SA, Elmorsy E, Al-Ghafari A, et al. Effect of amphotericin B-deoxycholate (Fungizone) on the mitochondria of Wistar rats’ renal proximal tubules cells. J Appl Toxicol. 2021;41(10):1620–1633. doi: 10.1002/jat.4151
  • Downes KJ, Hayes M, Fitzgerald JC, et al. Mechanisms of antimicrobial-induced nephrotoxicity in children. J Antimicrob Chemother. 2020;75(1):1–13. doi: 10.1093/jac/dkz325
  • O’Horo JC, Osmon DR, Abu Saleh OM, et al. Coadministration of liposomal Amphotericin B and contrast medium does not increase risk of kidney injury. Antimicrob Agents Chemother. 2017;61(8):e00323–17. doi: 10.1128/AAC.00323-17
  • Tragiannidis A, Gkampeta A, Vousvouki M, et al. Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opin Drug Saf. 2021;20(9):1061–1074. doi: 10.1080/14740338.2021.1922667
  • Trejtnar F, Mandíková J, Kočíncová J, et al. Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals. Antimicrob Agents Chemother. 2014;58(10):5650–5657. doi: 10.1128/AAC.02829-14
  • Gola J, Strzałka-Mrozik B, Kruszniewska-Rajs C, et al. A new form of amphotericin B – the complex with copper (II) ions – downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways: AmB-Cu2+ downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways. Pharmacol Rep. 2017a;69(1):22–28. doi: 10.1016/j.pharep.2016.09.008
  • Gola J, Strzałka-Mrozik B, Wieczorek E, et al. Amphotericin B-copper (II) complex alters transcriptional activity of genes encoding transforming growth factor-beta family members and related proteins in renal cells. Pharmacol Rep. 2017b;69(6):1308–1314. doi: 10.1016/j.pharep.2017.05.011
  • Gu L, Shi H, Zhang R, et al. Simultaneous determination of five specific and sensitive nephrotoxicity biomarkers in serum and urine samples of four drug-induced kidney injury models. J Chromatogr Sci. 2017;55(1):60–68. doi: 10.1093/chromsci/bmw150
  • Magalhães EP, Silva BP, Aires NL, et al. (–)-α-Bisabolol as a protective agent against epithelial renal cytotoxicity induced by amphotericin B. Life Sci. 2022;291:120271. doi: 10.1016/j.lfs.2021.120271
  • Espada R, Valdespina S, Alfonso C, et al. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int J Pharm. 2008;361(1–2):64–69. doi: 10.1016/j.ijpharm.2008.05.013
  • Sawangchan P, Alexandrino Júnior F, Alencar ÉN, et al. The role of aggregation and ionization in the chemical instability of Amphotericin B in aqueous methanol. Int J Pharm. 2023;632:122586. doi: 10.1016/j.ijpharm.2023.122586
  • Todke PA, Devarajan PV. In-silico approach as a tool for selection of excipients for safer amphotericin B nanoformulations. J Control Release. 2022;349:756–764. doi: 10.1016/j.jconrel.2022.07.030
  • Ramos GS, Vallejos VMR, Borges GSM, et al. Formulation of Amphotericin B in PEGylated liposomes for improved treatment of cutaneous Leishmaniasis by parenteral and oral routes. Pharmaceutics. 2022;14(5):989. doi: 10.3390/pharmaceutics14050989
  • Banshoya K, Kaneo Y, Tanaka T, et al. Synthesis and evaluation of styrene-maleic acid copolymer conjugated amphotericin B. Int J Pharm. 2019;572:118719. doi: 10.1016/j.ijpharm.2019.118719
  • Silva-Carvalho R, Leão T, Bourbon AI, et al. Hyaluronic acid-amphotericin B nanocomplexes: a promising anti-leishmanial drug delivery system. Biomater Sci. 2022a;10(8):1952–1967. doi: 10.1039/d1bm01769a
  • Jain K, Mehra NK, Jain NK. Nanotechnology in drug delivery: safety and toxicity issues. Curr Pharm Des. 2015a;21(29):4252–4261. doi: 10.2174/1381612821666150901103208
  • Ojha B, Jain VK, Mehra NK, et al. Nanotechnology: introduction and basic concepts. In: Dendrimers in nanomedicine; 2021. p. 1–17. doi: 10.1201/9781003029915
  • Jain K, Zhong J. Theranostic applications of nanomaterials. Curr Pharm Des. 2022;28(2):77. doi: 10.2174/138161282802211223150153
  • Patel P, Kumar K, Jain VK, et al. Nanotheranostics for diagnosis and treatment of breast cancer. Curr Pharm Des. 2023;29(10):732–747. doi: 10.2174/1381612829666230329122911
  • Tandel H, Bhatt P, Jain K, et al. In-vitro and in-vivo tools in emerging drug delivery scenario: challenges and updates. In: In-vitro and in-vivo tools in drug delivery research for optimum clinical outcomes; 2018. p. 1–24. doi: 10.1201/b22448-1
  • Gauro R, Jain K, Jain VK, et al. Macromolecular architecture and molecular modelling of dendrimers. In: Dendrimers in nanomedicine. Vol. 9781003029915; 2021. p. 77–88. doi: 10.1201/9781003029915
  • Ayyala RS, Suner SS, Bhethanabotla VR, et al. Fungal Keratitis Treatment Using Drug-Loaded Hyaluronic Acid Microgels. ACS Appl Bio Mater. 2022;5(8):3806–3815. doi: 10.1021/acsabm.2c00362
  • Juneja M, Suthar T, Pardhi VP, et al. Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases. Nanomedicine (Lond). 2022;17(11):793–812. doi: 10.2217/nnm-2022-0006
  • Kumar P, Kumar P, Singh N, et al. Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review. Front Bioeng Biotechnol. 2022;10:1016925. doi: 10.3389/fbioe.2022.1016925
  • Pardhi VP, Suthar T, Sharma A, et al. Bedaquiline fumarate microemulsion: formulation optimization, rheological characterization and in vitro studies. Nanomedicine (Lond). 2022;17(21):1529–1546. doi: 10.2217/nnm-2022-0132
  • Cuellar J, Parada-Díaz L, Garza J, et al. A theoretical analysis of interaction energies and intermolecular interactions between Amphotericin B and potential bioconjugates used in the modification of nanocarriers for drug delivery. Molecules. 2023;28(6):2674. doi: 10.3390/molecules28062674
  • Suthar T, Patel P, Singh P, et al. Hesperidin microemulsion: Formulation optimization, characterization, and in vitro evaluation. J Drug Deliv Sci Technol. 2023;80(104166):1–12. doi: 10.1016/j.jddst.2023.104166
  • Kumar P, Shivam P, Mandal S, et al. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity. Int J Nanomedicine. 2019;14:6073–6101. doi: 10.2147/IJN.S196421
  • Ehrenfreund-Kleinman T, Azzam T, Falk R, et al. Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Biomaterials. 2002;23(5):1327–1335. doi: 10.1016/S0142-9612(01)00251-4
  • Francis AP, Gurudevan S, Jayakrishnan A. Synthetic polymannose as a drug carrier: synthesis, toxicity and anti-fungal activity of polymannose-amphotericin B conjugates. J Biomater Sci Polym Ed. 2018;29(13):1529–1548. doi: 10.1080/09205063.2018.1469186
  • Gurudevan S, Francis AP, Jayakrishnan A. Amphotericin B-albumin conjugates: Synthesis, toxicity and anti-fungal activity. Eur J Pharm Sci. 2018;115:167–174. doi: 10.1016/j.ejps.2018.01.017
  • Ravichandran V, Jayakrishnan A. Synthesis and evaluation of anti-fungal activities of sodium alginate-amphotericin B conjugates. Int j biol macromol. 2018;108:1101–1109. doi: 10.1016/j.ijbiomac.2017.11.030
  • Shu C, Li T, Yang W, et al. Amphotericin B-conjugated polypeptide hydrogels as a novel innovative strategy for fungal infections. R Soc Open Sci. 2018;5(3):171814. doi: 10.1098/rsos.171814
  • Silva-Carvalho R, Leão T, Gama FM, et al. Covalent conjugation of Amphotericin B to hyaluronic acid: an injectable water-soluble conjugate with reduced toxicity and Anti-Leishmanial potential. Biomacromolecules. 2022b;23(3):1169–1182. doi: 10.1021/acs.biomac.1c01451
  • Correa T, Bazylinski DA, Garcia F, et al. A rapid and simple preparation of amphotericin B-loaded bacterial magnetite nanoparticles. RSC Adv. 2021;11(45):28000–28007. doi: 10.1039/D1RA03950D
  • Ghosh C, Varela-Aramburu S, Eldesouky HE, et al. Non-Toxic Glycosylated Gold Nanoparticle-Amphotericin B Conjugates Reduce Biofilms and Intracellular Burden of Fungi and Parasites. Adv Ther. 2021;4(5):2000293(1–8). doi: 10.1002/adtp.202000293
  • Gudz KY, Antipina LY, Permyakova ES, et al. Ag-doped and antibiotic-loaded hexagonal boron nitride nanoparticles as promising carriers to fight different pathogens. ACS Appl Mater Interfaces. 2021;13(20):23452–23468. doi: 10.1021/acsami.1c03775
  • Thanki K, Date T, Jain S. Enabling oral Amphotericin B delivery by merging the benefits of prodrug approach and nanocarrier-mediated drug delivery. ACS Biomater Sci Eng. 2023;9(6):2879–2890. doi: 10.1021/acsbiomaterials.0c01505
  • Anwar A, Siddiqui R, Hussain MA, et al. Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole. Parasitol Res. 2018;117(1):265–271. doi: 10.1007/s00436-017-5701-x
  • Ahmad A, Wei Y, Syed F, et al. Amphotericin B-conjugated biogenic silver nanoparticles as an innovative strategy for fungal infections. Microb Pathog. 2016;99:271–281. doi: 10.1016/j.micpath.2016.08.031
  • Kagan S, Ickowicz D, Shmuel M, et al. Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan. Antimicrob Agents Chemother. 2012;56(11):5603–5611. doi: 10.1128/AAC.00612-12
  • Jain K, Verma AK, Mishra PR, et al. Characterization and evaluation of amphotericin B loaded MDP conjugated poly(propylene imine) dendrimers. Nanomedicine. 2015b;11(3):705–713. doi: 10.1016/j.nano.2014.11.008
  • Jain K, Verma AK, Mishra PR, et al. Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation. Antimicrob Agents Chemother. 2015c;59(5):2479–2487. doi: 10.1128/AAC.04213-14
  • Falk R, Domb AJ, Polacheck I. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob Agents Chemother. 1999;43(8):1975–1981. doi: 10.1128/AAC.43.8.1975
  • Golenser J, Frankenburg S, Ehrenfreund T, et al. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother. 1999;43(9):2209–2214.
  • Nishi KK, Antony M, Mohanan PV, et al. Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi. Pharm Res. 2007;24(5):971–980.
  • Kagan S, Ickowicz DE, Domb AJ, et al. Unique aggregation of conjugated amphotericin B and its interaction with lipid membranes. Med Mycol. 2017;55(4):414–421. doi: 10.1093/mmy/myw099
  • Sokolsky-Papkov M, Domb AJ, Golenser J. Impact of aldehyde content on amphotericin B-dextran imine conjugate toxicity. Biomacromolecules. 2006;7(5):1529–1535. doi: 10.1021/bm050747n
  • Bagre A, Patel P, Naqvi S, et al. Chapter 1 – emerging concerns of infectious diseases and drug delivery challenge. In: Jain K Ahmad J, editors. Nanotheranostics for infectious diseases: design, characterization and application”. Elsevier; 2022. doi: 10.1016/B978-0-323-91201-3.00013-X
  • Dowari P, Roy S, Das S, et al. Mannose-decorated composite peptide hydrogel with thixotropic and syneresis properties and its application in treatment of leishmaniasis. Chem Asian J. 2022;17(18):e202200550. doi: 10.1002/asia.202200550
  • Galdopórpora JM, Martinena C, Bernabeu E, et al. Inhalable mannosylated rifampicin-curcumin co-loaded nanomicelles with enhanced in vitro antimicrobial efficacy for an optimized pulmonary tuberculosis therapy. Pharmaceutics. 2022;14(5):959.
  • Uehara K, Harumoto T, Makino A, et al. Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated siRNA. Nucleic Acids Res. 2022;50(9):4840–4859. doi: 10.1093/nar/gkac308
  • Ravichandran V, Kesavan V, Cojean S, et al. Polysorbate surfactants as drug carriers: tween 20-amphotericin B conjugates as anti-fungal and anti-leishmanial agents. Curr Drug Deliv. 2018a;15(7):1028–1037. doi: 10.2174/1567201815666180503122829
  • Ravichandran V, Kothandaraman GP, Bories C, et al. Synthetic polysaccharides as drug carriers: synthesis of polyglucose-Amphotericin B conjugates and in vitro evaluation of their anti-fungal and anti-leishmanial activities. J Nanosci Nanotechnol. 2018b;18(4):2405–2414. doi: 10.1166/jnn.2018.14296
  • Banshoya K, Kaneo Y, Tanaka T, et al. Development of an amphotericin B micellar formulation using cholesterol-conjugated styrene-maleic acid copolymer for enhancement of blood circulation and antifungal selectivity. Int J Pharm. 2020;589:119813. doi: 10.1016/j.ijpharm.2020.119813
  • Arias ER, Angarita-Villamizar V, Baena Y, et al. Phospholipid-Conjugated PEG-b-PCL copolymers as precursors of micellar vehicles for Amphotericin B. Polymers. 2021;13(11):1747. doi: 10.3390/polym13111747
  • Rodriguez YJ, Quejada LF, Villamil JC, et al. Development of Amphotericin B micellar formulations based on copolymers of Poly(ethylene glycol) and Poly(ε-caprolactone) conjugated with retinol. Pharmaceutics. 2020;12(3):196. doi: 10.3390/pharmaceutics12030196
  • Xu H, Teng F, Zhou F, et al. Linolenic acid-modified MPEG-PEI micelles for encapsulation of amphotericin B. Future Med Chem. 2019;11(20):2647–2662. doi: 10.4155/fmc-2018-0580
  • Song Z, Wen Y, Deng P, et al. Linolenic acid-modified methoxy poly (ethylene glycol)-oligochitosan conjugate micelles for encapsulation of amphotericin B. Carbohydr Polym. 2019;205:571–580. doi: 10.1016/j.carbpol.2018.10.086
  • Wang Y, Ke X, Voo ZX, et al. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B. Acta Biomater. 2016;46:211–220. doi: 10.1016/j.actbio.2016.09.036
  • Zhang P, Yang X, He Y, et al. Preparation, characterization, and toxicity evaluation of amphotericin B loaded MPEG-PCL micelles and its application for buccal tablets. Appl Microbiol Biotechnol. 2017;101(19):7357–7370.
  • Zhou L, Zhang P, Chen Z, et al. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans. Int J Nanomedicine. 2017;12:4269–4283. doi: 10.2147/IJN.S124264
  • Akbar N, Aslam Z, Siddiqui R, et al. Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules. AMB Express. 2021;11(1):104. doi: 10.1186/s13568-021-01261-1
  • Anwar A, Siddiqui R, Raza Shah M, et al. Gold nanoparticles conjugation enhances antiacanthamoebic properties of nystatin, fluconazole and Amphotericin B. J Microbiol Biotechnol. 2019;29(1):171–177. doi: 10.4014/jmb.1805.05028
  • Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011;7(5):632–639. doi: 10.1166/jbn.2011.1332
  • Jain V, Gupta A, Pawar VK, et al. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014;174(4):1309–1330. doi: 10.1007/s12010-014-1084-y
  • Amekyeh H, Billa N, Roberts C. Correlating gastric emptying of amphotericin B and paracetamol solid lipid nanoparticles with changes in particle surface chemistry. Int J Pharm. 2017;517(1–2):42–49. doi: 10.1016/j.ijpharm.2016.12.001
  • Singh A, Yadagiri G, Parvez S, et al. Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate. Mater Sci Eng C Mater Biol Appl. 2020;117:111279. doi: 10.1016/j.msec.2020.111279
  • Parvez S, Yadagiri G, Gedda MR, et al. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep. 2020;10(12243):1–14.
  • Thanki K, Date T, Jain S. Improved oral bioavailability and gastrointestinal stability of amphotericin B through fatty acid conjugation approach. Mol Pharm. 2019;16(11):4519–4529. doi: 10.1021/acs.molpharmaceut.9b00662
  • Skwarecki AS, Skarbek K, Martynow D, et al. Molecular Umbrellas Modulate the Selective Toxicity of Polyene Macrolide Antifungals. Bioconjug Chem. 2018;29(4):1454–1465. doi: 10.1021/acs.bioconjchem.8b00136
  • Savla R, Browne J, Plassat V, et al. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev Ind Pharm. 2017;43(11):1743–1758. doi: 10.1080/03639045.2017.1342654
  • Sleep D. Albumin and its application in drug delivery. Exp Opin Drug Deliv. 2015;12(5):793–812. doi: 10.1517/17425247.2015.993313
  • Stevens CA, Kaur K, Klok HA. Self-assembly of protein-polymer conjugates for drug delivery. Adv Drug Deliv Rev. 2021;174:447–460. doi: 10.1016/j.addr.2021.05.002
  • Efimova SS, Tevyashova AN, Olsufyeva EN, et al. Pore-forming activity of new conjugate antibiotics based on amphotericin B. PloS One. 2017;12(11):e0188573. doi: 10.1371/journal.pone.0188573
  • Jain K, Jain NK. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discov Today. 2013;18(23–24):1272–1281. doi: 10.1016/j.drudis.2013.08.005
  • Jain V, Jain K. Molecular targets and pathways for the treatment of visceral leishmaniasis. Drug Discov Today. 2018;23(1):161–170. doi: 10.1016/j.drudis.2017.09.006
  • Park SC, Kim YM, Lee JK, et al. Targeting and synergistic action of an antifungal peptide in an antibiotic drug-delivery system. Journal Of Controlled Release. 2017;256:46–55. doi: 10.1016/j.jconrel.2017.04.023
  • Li X, Huang R, Tang FK, et al. Red-emissive guanylated polyene-functionalized carbon dots arm oral epithelia against invasive fungal infections. ACS Appl Mater Interfaces. 2019;11(50):46591–46603.
  • Baibek A, Üçüncü M, Short B, et al. Dyeing fungi: amphotericin B based fluorescent probes for multiplexed imaging. Chem Commun (Camb). 2021;57(15):1899–1902. doi: 10.1039/D0CC08177A
  • Ferreira SMZMD, Carneiro HC, Alves RB, et al. A UBI 31-38 peptide-coumarin conjugate: photophysical features, imaging tracking and synergism with Amphotericin B against Cryptococcus. CTMC. 2018;18(2):157–163.
  • Joyson N, Pathak A, Jain K. One platform comparison of polymeric and lipidic nanoparticles for the delivery of Amphotericin B. AAPS PharmScitech. 2023;24(8):226(1–22616. doi: 10.1208/s12249-023-02672-y
  • Tevyashova AN, Olsufyeva EN, Solovieva SE, et al. Structure-antifungal activity relationships of polyene antibiotics of the amphotericin B group. Antimicrob Agents Chemother. 2013;57(8):3815–22. doi: 10.1128/AAC.00270-13
  • Carolus H, Pierson S, Lagrou K, et al. Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance. J Fungi (Basel). 2020;6(4):321. doi: 10.3390/jof6040321
  • Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2017;8(2):169–185. doi: 10.1080/21505594.2016.1196300
  • Agarwal V, Kumia K, Gupta A, et al. Local injection of amphotericin B: novel use in the treatment of fungal maxillary sinusitis. Int J Oral Maxillofac Surg. 2023;52(12):1282–1285. doi: 10.1016/j.ijom.2023.07.008
  • Johri N, Choudhary A, Rawat U, et al. Amphotericin-B-induced chronic kidney disease in a post-covid-19 patient with widespread rhinocerebral mucormycosis and pneumonia: A case report. Curr Drug Saf. 2023. doi: 10.2174/1574886318666230804101539
  • Karadeniz Uğurlu Ş, Selim S, Kopar A, et al. Rhino-orbital Mucormycosis: clinical findings and treatment outcomes of four cases. Turk J Ophthalmol. 2015;45(4):169–174. doi: 10.4274/tjo.82474
  • Pathak A, Jain K. Dendrimer–drug conjugates. In Polymer-drug conjugates: linker chemistry, protocols and applications; 2023. p. 315–345. Elsevier. doi: 10.1016/B978-0-323-91663-9.00005-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.